Biography

Dr. Linjun Shi’s research focuses on immune escape mechanism of oral potentially malignant disorders and application of non-invasive screening technology in potentially malignant disorders. 

Oral leukoplakia is a representative disease of oral potentially malignant disorders, and it is of great significance to advance the treatment of tumor immune checkpoints to the stage of precancerous lesions. The previous study of our group found that PD-L1 was significantly up-regulated in human and mouse oral leukoplakia tissues, and PD-1 monoclonal antibody can effectively treat early-stage leukoplakia in mice (Shi L, et al. Molecular Therapy. 2022), but the mechanism of some mice not responding to immunotherapy and immune escape needs to be studied. The research interests of our group are to elucidate the mechanism of immune escape of oral potentially malignant disorders from the perspective of PD-L1 protein post-translational modification, and to explore potential therapeutic targets, to provide new strategies for the precise treatment of oral potentially malignant disorders. 

The early diagnosis of oral potentially malignant disorders and the prediction of cancer risk are the predicaments in clinical work. The previous research of our group confirmed that non-invasive screening technology (including autofluorescence technology and quantitative analysis of DNA content) can be used in high-risk oral precancerous lesions. Diagnosis has shown application value (Shi L, et al. Oral Oncology. 2015; Shi L, et al. Oral Oncology. 2019; Shi L, et al. Oral Oncology. 2020; Shi L, et al. Cancer Medicine. 2020; Shi L, et al. Oral Oncology. 2020; Shi L, et al. Cancer Biology & Medicine. 2021; Shi L, et al. Oral Oncology. 2021). The research interest of our group is to use the large-sample disease-specific cohort of the Ninth People’s Hospital, combined with artificial intelligence image analysis technology, to improve the diagnostic efficiency of non-invasive screening technology, and to evaluate its effect on predicting cancer risk. The goal of our group is to provide high-level evidence-based medical evidence. 

Dr. Linjun Shi has undertaken several scientific research projects, including general projects of the National Natural Science Foundation of China and Shanghai Natural Science Foundation. Dr. Linjun Shi has published several SCI papers, including papers in the first area of JCR, and participated in the editing of several books.